Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica's inFoods® IBS Test in the U.S.

Core Insights - Biomerica has entered a marketing services arrangement with Henry Schein to promote its inFoods® IBS test across the U.S., excluding New York, marking a significant step in its commercialization strategy [1][2][3] Company Overview - Biomerica, Inc. is a global biomedical technology company focused on developing diagnostic and therapeutic products for gastrointestinal and inflammatory diseases [13] - Henry Schein, Inc. is the largest provider of health care solutions to office-based dental and medical practitioners, with over $12 billion in annual sales in 2024 and a strong distribution network [2][11] Product Details - The inFoods® IBS test is a diagnostic-guided therapy that identifies food triggers for IBS symptoms, allowing for personalized dietary recommendations [6] - The test has shown significant efficacy in clinical studies, particularly for IBS-M patients, with 59.6% of patients in the treatment group achieving the FDA's endpoint for abdominal pain reduction [4][7] Market Context - IBS affects approximately 10% to 15% of adults in the U.S., leading to a lower quality of life and decreased work productivity for those affected [5] - The partnership with Henry Schein is expected to enhance the adoption of this non-drug therapy, addressing a significant unmet need in the IBS market [2][3]